Prosecution Insights
Last updated: November 20, 2026

Kevin E Weddington, USPTO Patent Examiner

Listed by the USPTO as WEDDINGTON, KEVIN E

Tech Center 1600 • Art Units: 1613 1614 1621 1629

This examiner grants 75% of resolved cases

Analysis

Kevin E. Weddington is assigned to USPTO Tech Center 1600 and Art Unit 1613. His record includes 1477 resolved cases, an allowance rate of 75.4%, and a median of 903 days to allowance. The interview lift is 9.7%, so the recorded association between interviews and allowance is positive but limited relative to the overall allowance result.

The principal companies shown are Deciphera Pharmaceuticals LLC, Antecip Bioventures Ii LLC, and Mindset Pharma Inc. The leading firms are COOLEY LLP, Baker, Donelson, Bearman, Caldwell & Berkowitz, PC, and BakerHostetler. This combination of substantial case volume and a positive interview association may help practitioners frame prosecution planning for matters assigned to this examiner.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

75.4%
Allow Rate
+15.4% vs TC avg
1,509
Total Applications
+9.7%
Interview Lift
903
Avg Prosecution Days
Based on 1477 resolved cases, 2023–2026

Rejection Statute Breakdown

1.4%
§101 Eligibility
17.0%
§102 Novelty
28.2%
§103 Obviousness
28.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19684927 BUPROPION AS A MODULATOR OF DRUG ACTIVITY Non-Final OA ANTECIP BIOVENTURES II LLC
18591870 POLYAMINO IODINATED COMPOUNDS AND RADIOPAQUE HYDROGELS FORMED THEREFROM Final Rejection Boston Scientific Scimed, Inc.
18683842 INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Non-Final OA Mindset Pharma Inc.
18700358 IMIDAZO[1,2-A]PYRIDINE DERIVATIVES Non-Final OA SYNGENTA CROP PROTECTION AG
18970577 COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMA WITH A DUAL TARGETING ANTI-TUMOR COMPOSITION Non-Final OA Northwestern University
18043436 N-Linked Glycosylation Inhibitors and Methods of Using Same Non-Final OA YALE UNIVERSITY
18892030 EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT Non-Final OA Alto Neuroscience, Inc.
18843652 METHOD FOR PREVENTING OR TREATING HEARING LOSS Non-Final OA MACKAY MEDICAL COLLEGE
17482364 Post Cov19 Vaccine Remedies Non-Final OA IPRX, LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Kevin E Weddington's allowance rate?

75.4% of resolved applications examined by Kevin E Weddington were allowed (1,477 resolved cases), compared with 33.8% across Art Unit 1613 over the last five years.

Does an interview help with examiner Kevin E Weddington?

This examiner's interview lift is +9.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Kevin E Weddington take to allow a patent?

Applications allowed by Kevin E Weddington took 903 days on average from filing to allowance.

Which art unit does examiner Kevin E Weddington work in?

Kevin E Weddington examines applications in Art Unit 1613 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month